Adaptive Bayesian analysis of serum creatinine as a marker for drug-induced renal impairment in an early-phase clinical trial

Clinical Chemistry

Volumn 58, Issue 11, 2012, Pages 1592-1596

  Sottas, Pierre Edouard ^a   Kapke, Gordon F ^b   Leroux, Jean Marc ^a  

^a Hôpitai de la Tour   (Switzerland)

^b Labcorp Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN; PLACEBO;

ADULT; ARTICLE; BAYES THEOREM; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DISEASE MARKER; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; NORMAL HUMAN; PATIENT MONITORING; RISK BENEFIT ANALYSIS;

ADULT; BAYES THEOREM; BIOMARKERS, PHARMACOLOGICAL; CREATININE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HUMANS; REFERENCE VALUES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84868143694     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.193698     Document Type: Article

References (10)

1. Slocum JL, Heung M, Pennathur S. Marking renal injury: Can we move beyond serum creatinine? Transl Res 2012;159:277-89.
2. Ferguson MA, Waikar SS. Established and emerging markers of kidney function. Clin Chem 2012;58:680-9.
3. Edelstein CL. Biomarkers of acute kidney injury. Adv Chronic Kidney Dis 2008;15:222-34. (Pubitemid 351822595)
4. Ricós C, Iglesias N, García-Lario JV, Simón M, Cava F, Hernández A, et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007;44:343-52. (Pubitemid 351724670)
5. Reinhard M, Erlandsen EJ, Randers E. Biological variation of cystatin C and creatinine. Scand J Clin Lab Invest 2009;69:831-6.
6. Kwong YT, Stevens LA, Selvin E, Zhang YL, Greene T, Van Lente F, et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis 2010;56:39-49.
7. Sottas PE, Baume N, Saudan C, Schweizer C, Kamber M, Saugy M. Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio. Biostatistics 2007;8:285-96. (Pubitemid 46569590)
8. Sottas PE, Kapke GF, Vesterqvist O, Leroux JM. Patient-specific measures of a biomarker for the generation of individual reference intervals: hemoglobin as example. Transl Res 2011;158:360-8.
9. Sottas PE, Robinson N, Rabin O, Saugy M. The athlete biological passport. Clin Chem 2011;57:969-76.
10. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 2010;28:455-62.